HighTower Advisors’s Alaunos Therapeutics TCRT Stock Holding History

HighTower Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-367	Closed	-$7K	–	3847
2023 Q3	$7K	Hold	367	–	–	﹤0.01%	3410
2023 Q2	$28K	Buy	367 +100	+37%	+$8.09K	﹤0.01%	3226
2023 Q1	$25K	Hold	267	–	–	﹤0.01%	3128
2022 Q4	$25K	Sell	267 -2	-0.7%	-$290	﹤0.01%	3111
2022 Q3	$69K	Hold	269	–	–	﹤0.01%	2834
2022 Q2	$51K	Sell	269 -16	-6%	-$1.53K	﹤0.01%	2907
2022 Q1	$27K	Hold	285	–	–	﹤0.01%	3133
2021 Q4	$46K	Sell	285 -61	-18%	-$13.4K	﹤0.01%	3033
2021 Q3	$95K	Buy	346 +3	+0.9%	+$917	﹤0.01%	2857
2021 Q2	$136K	Sell	343 -50	-13%	-$23.3K	﹤0.01%	2746
2021 Q1	$213K	Buy	+393	New	+$245K	﹤0.01%	2562
2020 Q4	–	Sell	-333	Closed	-$125K	–	2799
2020 Q3	$125K	Sell	333 -331	-50%	-$146K	﹤0.01%	2201
2020 Q2	$328K	Sell	664 -211	-24%	-$94.1K	﹤0.01%	1684
2020 Q1	$322K	Sell	875 -25	-3%	-$12.9K	﹤0.01%	1526
2019 Q4	$636K	Sell	900 -110	-11%	-$75.7K	﹤0.01%	1341
2019 Q3	$648K	Buy	1,010 +62	+7%	+$49.2K	﹤0.01%	1382
2019 Q2	$827K	Sell	948 -85	-8%	-$58.5K	﹤0.01%	1281
2019 Q1	$595K	Buy	1,033 +322	+45%	+$135K	﹤0.01%	1367
2018 Q4	$198K	Buy	711 +6	+0.9%	+$2.37K	﹤0.01%	1849
2018 Q3	$337K	Buy	705 +32	+5%	+$13.7K	﹤0.01%	1671
2018 Q2	$306K	Sell	673 -51	-7%	-$32.3K	﹤0.01%	1675
2018 Q1	$427K	Buy	724 +197	+37%	+$123K	﹤0.01%	1502
2017 Q4	$326K	Buy	527 +220	+72%	+$158K	﹤0.01%	1661
2017 Q3	$282K	Sell	307 -15	-5%	-$13.3K	﹤0.01%	1717
2017 Q2	$300K	Sell	322 -86	-21%	-$84.3K	﹤0.01%	1629
2017 Q1	$388K	Sell	408 -3	-0.7%	-$2.79K	﹤0.01%	1441
2016 Q4	$329K	Sell	411 -15	-4%	-$13.5K	﹤0.01%	1425
2016 Q3	$361K	Buy	426 +190	+81%	+$153K	﹤0.01%	1384
2016 Q2	$194K	Sell	236 -17	-7%	-$18.5K	﹤0.01%	1503
2016 Q1	$281K	Buy	253 +17	+7%	+$17.4K	﹤0.01%	1639
2015 Q4	$290K	Sell	236 -111	-32%	-$184K	﹤0.01%	1590
2015 Q3	$465K	Buy	347 +111	+47%	+$183K	0.01%	1234
2015 Q2	$426K	Buy	236 +16	+7%	+$24.8K	0.01%	1075
2015 Q1	$355K	Buy	220 +97	+79%	+$144K	0.01%	1179
2014 Q4	$94K	Hold	123	–	–	﹤0.01%	1479
2014 Q3	$49K	Buy	123 +16	+15%	+$7.71K	﹤0.01%	1459
2014 Q2	$64K	Hold	107	–	–	﹤0.01%	1499
2014 Q1	$73K	Hold	107	–	–	﹤0.01%	1397
2013 Q4	$69K	Hold	107	–	–	﹤0.01%	1401
2013 Q3	$63K	Hold	107	–	–	﹤0.01%	1235
2013 Q2	$34K	Buy	+107	New	+$29.7K	﹤0.01%	1221

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCA

Magnolia Capital Advisors Jackson, Mississippi $509M AUM 18.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

HighTower Advisors's TCRT Position: Q4 2023 in Review

HighTower Advisors sold out of Alaunos Therapeutics (TCRT) in Q4 2023, closing a stake of 367 shares — an estimated $7K sold.

HighTower Advisors first reported a position in TCRT in Q2 2013 and held it in 41 quarters. The position peaked at $827K in Q2 2019. 82 funds tracked by Wall St. Rank hold TCRT as of Q4 2023.

HighTower Advisors reported no remaining Alaunos Therapeutics position as of Q4 2023 after selling out during the quarter.
HighTower Advisors sold 367 Alaunos Therapeutics shares in Q4 2023, an estimated $7K.
HighTower Advisors first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 41 quarters.
HighTower Advisors's Alaunos Therapeutics position peaked at $827K in Q2 2019.
82 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2023.

Based on HighTower Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.